Standard of Care and Managing Treatment Risks
At a Glance
PACNS is usually treated in two phases: high-dose steroids, often with cyclophosphamide or rituximab, to control active inflammation, followed by longer-term maintenance medicine to prevent relapse. Regular blood, kidney, infection, and side-effect monitoring is essential.
Treating Primary Angiitis of the Central Nervous System (PACNS) is a long-term process that requires a careful balance between calming aggressive inflammation and managing the side effects of powerful medications. Because the disease is so rare, there have been no large-scale randomized controlled trials to pinpoint a single “best” treatment; instead, doctors rely on expert consensus and data from groups of patients followed over time [1][2].
The Two-Phase Treatment Strategy
The standard approach to PACNS is typically divided into two distinct parts: induction and maintenance [1][3]. The specific choices are highly individualized based on disease severity, vessel phenotype, diagnostic certainty, and specialist judgment.
Phase 1: Induction (Calming the Inflammation)
The goal of induction is to stop the active inflammation in your blood vessels as quickly as possible to prevent further brain injury [3].
- Glucocorticoids (Steroids): High-dose steroids (such as prednisone or intravenous methylprednisolone) are generally the first line of defense [1]. They work rapidly to reduce swelling and immune activity.
- Cyclophosphamide: Often combined with steroids, cyclophosphamide is a potent immunosuppressant widely used to get the disease under control [3][4]. An international survey found that 84% of specialists use this combination [3].
- Rituximab: This biologic medication targets specific immune cells (B-cells) and is an important, commonly used induction option depending on specialist judgment, comorbidities, or if fertility preservation is a priority [5][6].
Phase 2: Maintenance (Preventing Relapse)
Once the disease is in remission (no longer active), your doctor will transition you to “maintenance” medications. These are typically taken for a longer duration—often individualized over several years—to prevent the disease from coming back (a relapse) [3][7]. Common maintenance options include:
Managing Treatment Risks and Monitoring
The medications used for PACNS are powerful. Never stop or rapidly taper your steroids or immunosuppressants without instructions from your treating team. Your care team will monitor you for side effects to ensure the treatment remains safe.
Steroid Side Effects
High-dose steroids can cause high blood sugar, increased blood pressure, mood changes (“steroid euphoria” or depression), and bone thinning (osteoporosis) [8]. To protect your health, doctors often prescribe Vitamin D, calcium supplements, or bone-strengthening medications [1]. Adrenal-steroid protection is also carefully managed during tapering.
Immunosuppressant Safety and Infection Precautions
Medications like cyclophosphamide and rituximab require particularly strict monitoring:
- Infection Risk: They significantly lower your white blood cell count, making you vulnerable [5]. You will need regular blood tests (often every 1–2 weeks initially) to check your CBC (complete blood count) [1]. Doctors frequently prescribe prophylactic antibiotics to prevent specific infections like Pneumocystis pneumonia (PJP). For rituximab, Hepatitis B screening is required to prevent viral reactivation. Vaccination planning is critical and should ideally happen before treatment.
- Bladder and Kidney Health: Cyclophosphamide can irritate the bladder wall (hemorrhagic cystitis) or affect kidney function. You will need routine urinalysis monitoring. Blood in the urine requires prompt medical attention. Doctors may prescribe a protective drug called mesna and tailor hydration based on your kidney/heart health [9].
- Fertility and Pregnancy: Cyclophosphamide can impact the ability to have children in the future, and several maintenance drugs carry pregnancy risks. It is vital to discuss fertility preservation (like egg or sperm freezing) and contraception counseling before starting the medication [9].
🚨 Urgent: When to Call Your Care Team
While immunosuppressed, you must be vigilant. Contact your care team urgently (same-day) if you develop:
- Fever, chills, or new severe body aches.
- Shortness of breath or a new persistent cough.
- Painful urination or any visible blood in the urine.
- A new severe skin rash.
- Severe mood changes or depression.
(Remember: Sudden focal weakness, seizures, or thunderclap headaches mean you should call 911).
What About Other Treatments?
You may hear about treatments used for other types of systemic vasculitis. While sometimes used, they are not universally standard for PACNS:
- Plasma Exchange (Plasmapheresis): This process filters the blood. While used in some systemic vasculitis cases that affect the kidneys, there is no strong evidence that it routinely helps in PACNS unless there is a very specific complication [10][11].
- Avacopan: This is a newer drug used in systemic ANCA-associated vasculitis to reduce the need for steroids, but currently, evidence does not establish its standard use in PACNS [12][13].
Because of the complexity of these medications, the most recent guidelines strongly recommend that your care be managed by a multidisciplinary team at a specialized center [1].
Common questions in this guide
What is the usual treatment plan for PACNS?
How long will I need treatment for primary CNS vasculitis?
What tests are needed while taking PACNS medicines?
Which PACNS treatment side effects need urgent attention?
Can PACNS treatment affect fertility or pregnancy?
Are plasma exchange and avacopan standard treatments for PACNS?
Can I stop my PACNS steroids when I feel better?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on the severity of my disease, do you recommend starting with cyclophosphamide or rituximab alongside steroids?
- 2.What is the specific monitoring plan for my white blood cell counts and kidney function while on these medications?
- 3.How long do you anticipate I will need to be on the 'induction' phase before switching to maintenance therapy?
- 4.What specific measures (like medications or vaccinations) should I take to prevent infections while my immune system is suppressed?
- 5.How will we decide when it is safe to begin tapering my steroid dose?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (13)
- 1
European Stroke Organisation (ESO) guidelines on Primary Angiitis of the Central Nervous System (PACNS).
Pascarella R, Antonenko K, Boulouis G, et al.
European stroke journal 2023; (8(4)):842-879 doi:10.1177/23969873231190431.
PMID: 37903069 - 2
Primary angiitis of the central nervous system.
Meghashyam S, Serajee FJ, Prakash AV, et al.
Current opinion in immunology 2025; (98()):102691 doi:10.1016/j.coi.2025.102691.
PMID: 41270340 - 3
Diagnosis and management of adult primary angiitis of the central nervous system: an international survey on current practices.
Nehme A, Lanthier S, Boulanger M, et al.
Journal of neurology 2023; (270(4)):1989-1998 doi:10.1007/s00415-022-11528-7.
PMID: 36538155 - 4
Disease Characteristics and Treatments Associated with Outcome in Primary Angiitis of the Central Nervous System-A Multicenter Cohort Study in 163 Patients.
Fisse AL, Bonberg N, Beuker C, et al.
Annals of neurology 2025; (98(4)):883-893 doi:10.1002/ana.27295.
PMID: 40546217 - 5
Rituximab treatment in Chinese patients with primary angiitis of the central nervous system.
Wei YZ, Wang HB, Yin LL, et al.
Frontiers in neurology 2025; (16()):1554989 doi:10.3389/fneur.2025.1554989.
PMID: 40201016 - 6
Rituximab for refractory primary angiitis of the central nervous system: Experience in two patients.
Paramasivan NK, Sundaram S, Sharma DP, et al.
Multiple sclerosis and related disorders 2021; (51()):102907 doi:10.1016/j.msard.2021.102907.
PMID: 33773272 - 7
Relapse rates and long-term outcome in primary angiitis of the central nervous system.
Schuster S, Ozga AK, Stellmann JP, et al.
Journal of neurology 2019; (266(6)):1481-1489 doi:10.1007/s00415-019-09285-1.
PMID: 30904954 - 8
Primary angiitis of the central nervous system: diagnosis and treatment.
Beuker C, Schmidt A, Strunk D, et al.
Therapeutic advances in neurological disorders 2018; (11()):1756286418785071 doi:10.1177/1756286418785071.
PMID: 30034536 - 9
Primary angiitis of central nervous system - A challenging diagnosis.
Paul SA, Roy D, Mondal GP, et al.
Journal of neuroimmunology 2022; (366()):577844 doi:10.1016/j.jneuroim.2022.577844.
PMID: 35299076 - 10
Need for Swift Diagnosis of Primary Angiitis of Central Nervous System: A Case With Focal Motor Seizures of Hand Progressing to Aphasia.
Arif S, Arif S, Liaqat J, et al.
Cureus 2020; (12(10)):e10803 doi:10.7759/cureus.10803.
PMID: 33163307 - 11
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.
Hellmich B, Sanchez-Alamo B, Schirmer JH, et al.
Annals of the rheumatic diseases 2024; (83(1)):30-47 doi:10.1136/ard-2022-223764.
PMID: 36927642 - 12
ANCA-Associated Vasculitic Neuropathies: A Review.
Koike H, Nishi R, Ohyama K, et al.
Neurology and therapy 2022; (11(1)):21-38 doi:10.1007/s40120-021-00315-7.
PMID: 35044596 - 13
Avacopan, a selective C5a receptor antagonist, for anti-neutrophil cytoplasmic antibody-associated vasculitis.
Harigai M, Takada H
Modern rheumatology 2022; (32(3)):475-483 doi:10.1093/mr/roab104.
PMID: 34984461
This page explains PACNS treatment phases and medication safety for informational purposes only and does not constitute medical advice. Your specialist team should tailor treatment, monitoring, and steroid tapering to your situation.
Get notified when new evidence is published on granulomatous angiitis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.